Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05763407 · ClinicalTrials.gov registry record · NA
Early Feasibility Study of the NORM™ System in Heart Failure Patients (FUTURE-HFII)
A NA study of Heart Failure, sponsored by Foundry Innovation & Research 1, Limited (FIRE1).
- Recruiting
- Registry status
- NA
- Development phase
- 25
- Enrollment target
- 8
- Study locations
NCT05763407: Recruiting NA study of Heart Failure, sponsored by Foundry Innovation & Research 1, Limited (FIRE1).
NCT05763407 is a NA study of Heart Failure that is actively recruiting participants, run by Foundry Innovation & Research 1, Limited (FIRE1). The registered enrollment target is 25 participants, below the 2,049-participant average among 397 other Heart Failure trials with a reported enrollment target (99% lower). The trial reports 8 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05763407, a NA study of Heart Failure, is actively recruiting participants, sponsored by Foundry Innovation & Research 1, Limited (FIRE1).
- RECRUITING
- Registry status
- NA
- Development phase
- 25 participants
- Enrollment target
- 8
- Study locations
Study Summary
Early Feasibility Study of the NORM™ System in Heart Failure Patients
Primary Outcome
Procedural success defined as Sensor deployment at the intended site without procedural related SAEs
Conditions Studied
Interventions
- DEVICE NORM™ System
Study Locations (8)
New York
- Columbia University Irving Medical Center/ New York Presbyterian Hospital - New York
- Rochester General Hospital - Rochester
Ohio
- Cleveland Clinic - Cleveland
- The Ohio State University Wexner Medical Center - Columbus
Minnesota
- University of Minnesota Medica Center - Minneapolis
North Carolina
- Duke University Medical Center - Durham
South Carolina
- Prisma Health - Greenville
Texas
- Austin Heart Central at the Heart Hospital of Austin - Austin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2023-06-19 |
| Est. Completion | 2027-12 |
| Phase | NA |
What NCT05763407 shows while recruiting
NCT05763407 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 2,049-participant average among 397 other Heart Failure trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Heart Failure appearing as the primary indexed condition, and to 1 intervention - of which NORM™ System is the first listed.
NCT05763407 lists 8 locations in 6 states (New York, Ohio, Minnesota).
Frequently Asked Questions
What is clinical trial NCT05763407 about?
NCT05763407 is a clinical study titled "Early Feasibility Study of the NORM™ System in Heart Failure Patients (FUTURE-HFII)". Early Feasibility Study of the NORM™ System in Heart Failure Patients
What is the current status of trial NCT05763407?
This trial is currently recruiting. It is a NA study. The enrollment target is 25 participants. The study started on 2023-06-19. Estimated completion is 2027-12.
What conditions does trial NCT05763407 study?
This clinical trial studies the following conditions: Heart Failure.
What interventions are being tested in trial NCT05763407?
The interventions under investigation include: NORM™ System (DEVICE).
Who is sponsoring clinical trial NCT05763407?
This trial is sponsored by Foundry Innovation & Research 1, Limited (FIRE1), which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05763407 being conducted?
This trial has 8 study locations across Minnesota, New York, North Carolina, Ohio, South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heart Failure
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05763407's enrollment target sits among peer trials
25 336th of 397 higher than 61 of 397 other Heart Failure trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Heart Failure trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Diuretics Alone vs. Aortix Endovascular Device for Acute Heart Failure
RECRUITING · NA
-
iCardia4HF: Multi-component mHealth Intervention for Patients With Heart Failure
RECRUITING · NA
-
Optimizing Heart Failure Therapies Among Patients With Limited Access in Denver
RECRUITING · NA
-
Hemodynamic Monitoring to Prevent Adverse Events foLlowing cardiOgenic Shock Trial
RECRUITING · NA
-
Effect of a Quality Improvement Initiative to Address Social Determinants of Health on Rehospitalization Rates in Patients With Heart Failure
RECRUITING · NA
-
Mind Your Heart-II
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI